Cigna Group: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 1, 2019 and accepted by EDGAR at Aug 1, 2019, 13:26 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $38.82bn | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $76.77bn | us-gaap:Revenues |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $24.96bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $49.01bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months2019-04-01 to 2019-06-30 | $3.38bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2019-01-01 to 2019-06-30 | $6.68bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | $2.16bn | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | $4.39bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $348.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | $764.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | $1.41bn | us-gaap:ProfitLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | $2.78bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | $3.70 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | $7.26 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-04-01 to 2019-06-30 | $3.73 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2019-01-01 to 2019-06-30 | $7.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-04-01 to 2019-06-30 | 380,969,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2019-01-01 to 2019-06-30 | 382,496,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | $4.23bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $497.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2019-01-01 to 2019-06-30 | $866.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2019-06-30 | $3.61bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $20.71bn | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $154.40bn | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $31.87bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $110.55bn | us-gaap:Liabilities |
| Current portion of debt | At period end2019-06-30 | $2.31bn | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2019-06-30 | $990.0m | us-gaap:CommercialPaper |
| Shareholders' equity | At period end2019-06-30 | $43.81bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001739940-19-000007. Last ingested by Listed: Nov 5, 2026, 13:13 ET. Listed shows no prices and gives no investment advice.